Haemodynamic effects of roxatidine, an H2-receptor antagonist

Abstract

The haemodynamic effects of roxatidine were investigated in 12 patients with congestive heart failure (New York Heart Association class II) in a placebo-controlled, double-blind, randomized, cross-over study. Impedance and mechanocardiography were determined following successive 7-day treatment periods with placebo and roxatidine 150 mg once daily. Comparison with placebo values showed roxatidine to significantly increase the preejection period (109.7 +/- 2.7 ms versus 117.3 +/- 2.7 ms, 1.5 h after administration). Heart rate and blood pressure remained the same. In contrast to other, newer H2-receptor antagonists, which decrease stroke volume and/or cardiac output, roxatidine did not reduce these parameters but increased the preejection period and the ratio of the preejection period to the left ventricular ejection time, indicating a slight negative influence on cardiac performance.

Cardioprotective effect of histamine H2 antagonists in congestive heart failure

“…6 ). In sensitivity analysis, although there was no significant difference on cardiac output change between 2 groups at 6 hours after drug administration ( P = .43), the statistical difference still remained at 1.5 hours (MD: –0.37; 95%CI: –0.53 to –0.21, P < .001) and 3 hours (MD: –0.43; 95%CI: –0.59 to –0.27, P < .001) after removing 1 study, [ 28 ] in which the participants were CHF patients (Supplementary Fig. 4).…”

“…The participants of 6 studies [ 22 – 27 ] were healthy volunteers and the rest studies enrolled CHF patients. [ 16 , 28 – 30 ] The characteristics of the included studies were summarized in Table 1 .…”

“…Stroke volume was reported in 3 studies [ 22 , 27 , 28 ] involving 36 participants at 1.5, 3, and 6 hours after 1 week administration of placebo or H2RAs. As shown in Fig.…”

“…5 , there was no significant difference between the 2 groups on stroke volume change at 1.5, 3, and 6 hours after 1 week administration ( P > .05), indicating that H2RAs had no influence on stroke volume. The sensitivity analysis also showed no significant difference on stroke volume between placebo and H2RAs at 1.5, 3, and 6 hours after removing 1 study, [ 28 ] in which the participants were CHF patients (Supplementary Fig. 1).…”

“…Three studies [ 22 , 27 , 28 ] involving 36 participants reported the cardiac output at 1.5, 3, and 6 hours after successive administration of H2RAs or placebo for 1 week. Cardiac output was significantly reduced at 1.5 hours (MD: –0.28; 95%CI: –0.54 to –0.03, P = .03), 3 hours (MD: –0.37; 95%CI: –0.48 to –0.25, P < .001), and 6 hours (MD: –0.13; 95%CI: –0.24 to –0.02, P = .02) after administration of H2RAs (Fig.…”